Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst Pharmaceuticals (NAS:CPRX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Catalyst Pharmaceuticals Forward PE Ratio Related Terms
Catalyst Pharmaceuticals Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals Forward PE Ratio Chart
Catalyst Pharmaceuticals Annual Data
Trend
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
8.26
8.35
14.41
16.03
10.66
13.52
12.74
Catalyst Pharmaceuticals Quarterly Data
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
42.74
9.58
8.26
8.87
13.07
7.26
8.35
11.52
16.81
11.42
14.41
11.57
9.91
15.75
16.03
11.05
11.53
6.35
10.66
10.83
11.10
9.62
13.52
17.33
14.92
11.38
12.74
12.45
CPRX vs PBLS, ELVN, RLAY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Forward PE Ratio falls into.
Catalyst Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Catalyst Pharmaceuticals (CPRX) has a Forward PE Ratio of 16.12 as of Sep. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Catalyst Pharmaceuticals and its competitors. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #156 out of 384 companies in the Biotechnology industry, placing it in the top 40.6%.
Is Catalyst Pharmaceuticals' Forward PE Ratio too high?
Catalyst Pharmaceuticals' current Forward PE Ratio is 16.12. The Biotechnology industry median Forward PE Ratio is 20.76. Catalyst Pharmaceuticals' value of 16.12 is 22.4% below this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #156 out of 384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Forward PE Ratio compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #156 out of 384 companies for Forward PE Ratio. This puts Catalyst Pharmaceuticals in the upper half of its industry. The industry median Forward PE Ratio is 20.76. Catalyst Pharmaceuticals' value of 16.12 is 22.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 20.76, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current Forward PE Ratio of 16.12 is 22.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 20.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current Forward PE Ratio is 16.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current Forward PE Ratio is 16.12 and 22.4% below the Biotechnology industry median of 20.76. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current Forward PE Ratio is 16.12 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
Forward PE Ratio: 16.12
GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
Industry Position: 22.4% below the Biotechnology median (#156 of 384)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
